产品
编 号：F024476
分子式：C23H33N5O
分子量：395.54
分子式：C23H33N5O
分子量：395.54
产品类型
规格
价格
是否有货
结构图
CAS No: 1060524-97-1
产品详情
生物活性：
NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046). NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo.
体内研究：
NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice.Animal Model:Six to eight-week-old CD1 mice
Dosage:3.2 mg/kg
Administration:Hind limb injection; twice daily; 3 days
Result:Promoted functional and anatomical recovery of the NMJ.
体外研究：
NUCC-390 (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100.NUCC-390 (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors.NUCC-390 (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells.NUCC-390 (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4.
NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046). NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo.
体内研究：
NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice.Animal Model:Six to eight-week-old CD1 mice
Dosage:3.2 mg/kg
Administration:Hind limb injection; twice daily; 3 days
Result:Promoted functional and anatomical recovery of the NMJ.
体外研究：
NUCC-390 (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100.NUCC-390 (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors.NUCC-390 (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells.NUCC-390 (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备